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Background: Methicillin-resistant Staphylococcus aureus (MRSA) is a nosocomial (hospital-acquired)
pathogen of exceptional concern. It is responsible for life-threatening infections in both the hospital and
the community.
Aims: To determine the frequency of MRSA misidentification in hospitals in Tripoli, Libya using current
testing methods.
Methods: One hundred and seventy S. aureus isolates previously identified as MRSA were obtained from
three hospitals in Tripoli. All isolates were reidentified by culturing on mannitol salt agar, API 20
Staph System and retested for resistance to methicillin using the cefoxitin disk diffusion susceptibility test
and PBP2a. D-tests and vancomycin E-tests (Van-E-tests) were also performed for vancomycin-resistant
isolates.
Results: Of the 170 isolates examined, 86 (51%) were confirmed as MRSA (i.e. 49% were misidentified as
MRSA). Fifteen (17%) of the confirmed MRSA strains exhibited inducible clindamycin resistance. Of the 86
confirmed MRSA isolates, 13 (15%) were resistant to mupirocin, 53 (62%) were resistant to ciprofloxacin, 41
(48%) were resistant to trimethoprim-sulfamethoxazole, and none were resistant to linezolid. Although disc-
diffusion testing indicated that 23 (27%) of the isolates were resistant to vancomycin, none of the isolates were
vancomycin-resistant by Van-E-test.
Conclusions: Misidentification of nosocomial S. aureus as MRSA is a serious problem in Libyan hospitals.
There is an urgent need for the proper training of microbiology laboratory technicians in standard
antimicrobial susceptibility procedures and the implementation of quality control programs in microbiology
laboratories of Libyan hospitals.
Keywords: MRSA misidentiﬁcation; clindamycin resistance; E-test; vancomycin resistance
Received: 20 April 2010; Revised: 25 September 2010; Accepted: 12 October 2010; Published: 3 November 2010
T
he ability of Staphylococcus aureus to acquire
resistance to antibiotics has resulted in the emer-
gence of methicillin-resistant S. aureus (MRSA)
(1). MRSA is of great concern, as it causes life-threatening
nosocomial and community-acquired infections (24).
The resistance of MRSA to commonly used therapeutic
drugs is widely reported and associated with failed
therapy (5). Recent reports by Borg et al. provide
evidence of MRSA hyperendemicity in the southeast
Mediterranean (6, 7) with important consequences for
neighboring countries. However, these reports did not
include data from Libya.
Objectives: To evaluate current MRSA detection
methods and determine the rate at which S. aureus
isolates previously characterized as MRSA were misiden-
tified in three hospitals in Tripoli, Libya.
Materials and methods
Source of collection
There were 170 MRSA isolates from clinical and
environmental samples collected in the period 2008
2009 that were subjected to antimicrobial susceptibility
testing at the Biotechnology Research Center in Tripoli,
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referred to herein as hospitals A (n95), B (n13), and
C( n62), in Tripoli, Libya (Table 1). The collected
isolates had been identified previously in each hospital as
MRSA, initially based on cultural and microscopic
characteristics on blood agar API system and gram
staining for species determination as S. aureus. A non-
referenced disk diffusion susceptibility test against certain
and different antibiotics (i.e. oxacillin and cefoxitin) was
also used to identify S. aureus as MRSA. Notably, none
of the three hospitals used a quality control MRSA strain
such as a referenced in-house strain or international
recognized strain such as EMRSA-15.
Methicillin-resistant S. aureus (MRSA) determination
and susceptibility testing
The 170 isolates analyzed at the Biotechnology Research
Center were initially identified as S. aureus strains based
on selective culturing on mannitol salt agar (MSA) and
the API Staph test (bioMerieux). The determination of
MRSA was based on latex agglutination testing for
PBP2a and the cefoxitin disc diffusion susceptibility test
in accordance with the British Association of Antimicro-
bials and Chemotherapy guidelines (BSAC) (8).
Isolates identified as MRSA were cultured overnight
on sheep-blood agar, plated on Mueller-Hinton agar, and
analyzed in disk diffusion susceptibility tests using the
following antibiotics: ciprofloxacin (1 mg), erythromycin
(5 mg), clindamycin (2 mg), trimethoprim-sulfamethoxa-
zole (1.25 mg), mupirocin (5 mg), quinupristin/dalfopristin
(15 mg), vancomycin (5 mg), or linezolid (10 mg). After a
24-h incubation at 378C, the zone diameter was measured
and compared to MRSA-BSAC guidelines. The D-tests
were also performed on isolates that exhibited resistance
to erythromycin to test for inducible resistance to
clindamycin (MLSBi) (9). An E-test (AB bioMerieux)
was performed on MRSA isolates that were vancomycin
resistant in the disc diffusion susceptibility test, according
to BSAC guidelines. In-house confirmed, positive control
MRSA and MLSBiMRSA isolates were generously
provided by Dr. Ahmed MO, Department of Microbiol-
ogy and Parasitology, Faculty of Veterinary Medicine, Al
Fateh University
Results
All isolateswere furtherconfirmed as S.aureus. Of the 170
isolates previously identified at hospitals as MRSA, only
86 (51%) were confirmed as MRSA in the current study
(Tables 1 and 2). Of the 86 confirmed MRSA isolates, 23
(27%) were resistant to erythromycin. The D-testing for
inducible clindamycin resistance of erythromycin resistant
MRSA isolates revealed that only 15 (17%) exhibited the
MLSBi phenotype. Resistance to ciprofloxacin was iden-
tified in 62% (53/86) of the confirmed MRSA isolates, and
trimethoprim-sulfamethoxazole resistance was identified
in 48% (41/86) of the confirmed MRSA isolates. In
contrast to the relatively high levels of resistance to
fluoroquinolone and sulphonamide antibiotics, only 13
(15%) of the confirmed MRSA isolates were resistant to
mupirocin and none of the confirmed MRSA isolates
were resistant to linezolid. Out of the 86 confirmed
MRSA isolates, 23 (27%) were vancomycin resistant as
determined by the disc diffusion susceptibility test;
however, the E-test failed to confirm resistance to
vancomycin (Table 2).
Discussion
Until recently, most MRSA infections were acquired in
hospital settings. Today, MRSA infections can occur in
both rural and urban community settings (10, 11). In the
current study, we determined the frequency of MRSA
misidentification in hospitals in Tripoli, Libya using
current testing methods. We found that only 51% of
isolates previously identified as MRSAwere confirmed as
MRSA using current testing methods and standards
(Table 1). A large number of the confirmed MRSA
isolates in the current study exhibited resistance to
fluoroquinolones. The MRSA resistance to ciprofloxacin
is always associated with hospital-acquired MRSA, pro-
viding evidence that these isolates were hospital acquired
(12). The levels of ciprofloxacin resistance identified in
this Libyan study are relatively high relative to the average
level of 25% for the Eastern Mediterranean, which ranges
from 5% in Algeria to 40% in Turkey (6).
In contrast to the relatively high levels of resistance to
fluoroquinolone and sulphonamide antibiotics, only 13
(15%) of the confirmed MRSA isolates were mupirocin
resistant and none of the confirmed MRSA isolates were
resistant to linezolid. Similar levels of susceptibility to
mupirocin (77%) and linezolid (95%) have been reported
for MRSA isolates from Saudi Arabian hospitals (13).
Our data, showing 100% susceptibility to linezolid,
indicates that in Libya, as in Saudi Arabia, linezolid
remains a valuable tool for combating MRSA infections,
although it should be used cautiously. Resistance to
mupirocin, as determined by the E-test, occurred in
only a small proportion (i.e. 15%) of the confirmed
MRSA isolates, suggesting that mupirocin ointment, the
Table 1. Summary of results showing the percentage of
conﬁrmed MRSA isolates from the three different hospitals
Hospital
Number of previously
identified MRSA cases
Percentage of
confirmed MRSA cases
A 95 53 (56%)
B 13 10 (76%)
C 62 23 (37%)
Total 170 86 (51%)
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MRSA, may still be effective in human therapy (14).
Clindamycin is an important drug used for the treat-
ment of staphylococcal infections. The MLSB resistance
phenotypes (MLSBC and MLSBi) confer resistance to
multiple antimicrobial drug classes (i.e. macrolides, linco-
samides, and streptogramines B). Clindamycin resistance
was observed in 19/86 (22%) of the confirmed MRSA
isolates in the current study, with inducible resistance seen
in an additional 15 isolates. Notably, inducible resistance
to clindamycin in MRSA (MLSBi phenotype) has been
shown to compromise therapy (15, 16) indicating the need
for routine monitoring and susceptibility testing for both
constitutive and inducible clindamycin resistance (17, 18)
prior to therapy against MRSA infections in Libyan
hospitals.
The importance of including E-testing in determining
vancomycin resistance is illustrated by the difference
we observed in the number of vancomycin resistant
isolates between the disc diffusion susceptibility test (23
resistant isolates) and the E-test (0 resistant isolates, MIC
B2 mg/L). The interpretive criteria used here (8) set a
break point of B4 mg/l for susceptible strains. Although
the use of lower break points can indicate emerging
vancomycinresistance(19,20),ourvalueswerewellwithin
the susceptible range.
The disc diffusion susceptibility test is a valuable
method for the accurate, reliable detection of MRSA
and for monitoring resistance trends (2123). Herein, we
found that the results of disc diffusion susceptibility tests
indicated that 24% of our isolates were resistant to
vancomycin; however, the E-test did not confirm vanco-
mycin resistance for any of the same strains, indicating
that disk diffusion susceptibility testing alone is not
sufficient (8). Although the disc diffusion susceptibility
test should not be relied on to screen for resistance to
certain antimicrobials (e.g. vancomycin) it is recom-
mended as a preliminary screening test for resistance to
many antimicrobials (23, 24). The results of the current
study suggest that microbiologists in Libyan hospitals
should not rely on disk diffusion susceptibility tests as a
measure of vancomycin resistance. Furthermore, factors
such as how disks and media are stored and maintained
can certainly affect disk diffusion susceptibility test
results. Medium components concentration (i.e. NACl
of the MSA for instance) can affect the susceptibility
testing results (25). Moreover, many other factors can
also influence the results of disk diffusion susceptibility
tests such as incubation temperature (25), which could
lead to misidentification and misinterpretation. The
potential impact of these confounding factors should
certainly be considered in Libyan hospitals when testing
for MRSA.
It is extremely important for hospitals and microbiol-
ogists to follow standardized, reliable methods (e.g.
BSAC, CLSI [formerly NCCLS] guidelines) for determin-
ing susceptibility to antimicrobials (25). The use and
misuse of antimicrobials can lead to serious consequences,
which may lead to an increase in the development and
dissemination of MRSA (26). Meta-analysis linking
antibiotic resistance to antibiotic use, both at the indivi-
dual and institutional levels, has shown that antibiotic use
is associated with a 1.8-fold increased risk of patient-
acquired MRSA, and that glycopeptide or quinolone use
is associated with a 3-fold increased risk of patient-
acquired MRSA (9, 14). These results underscore the
need for a conservative approach to antimicrobial use.
The results of this study also indicate that tests currently
available and used in Tripoli hospitals are generating high
false positive rates of MRSA, which could lead to the
overuse of various classes of antibiotics and contribute to
increased resistance. As the hospital management systems
are identical in other parts of Libya, our findings indicate
the urgent need for a wider study including a variety of
scientific approaches to combat MRSA in Libya. Further-
more, implementing quality control programs in hospital
microbiology laboratories and training of laboratory
personnel should be mandatory.
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